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Abstract
Endothelial cells (EC) form the inner lining of blood vessels and are positioned between circulating lymphocytes and tissues.
Hypotheses have formed that EC may act as antigen presenting cells based on the intimate interactions with T cells, which
are seen in diseases like multiple sclerosis, cerebral malaria (CM) and viral neuropathologies. Here, we investigated how
human brain microvascular EC (HBEC) interact with and support the proliferation of T cells. We found HBEC to express MHC
II, CD40 and ICOSL, key molecules for antigen presentation and co-stimulation and to take up fluorescently labeled antigens
via macropinocytosis. In co-cultures, we showed that HBEC support and promote the proliferation of CD4+ and CD8+ T cells,
which both are key in CM pathogenesis, particularly following T cell receptor activation and co-stimulation. Our findings
provide novel evidence that HBEC can trigger T cell activation, thereby providing a novel mechanism for
neuroimmunological complications of infectious diseases.
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Introduction
The induction of adaptive cellular immunity is a function of
professional antigen presenting cells (APCs) such as dendritic cells,
which provide signal 1 (peptide-major histocompatibility complex
(MHC)), signal 2 (co-stimulatory molecules), and signal 3
(instructive cytokines) to naive T lymphocytes upon antigen
encounter [1].
Endothelial cells (EC) form the inner lining of blood vessels and
are positioned between circulating lymphocytes and peripheral
tissues. As such, EC are the first cells with which T cells come into
direct contact in the circulation. The hypothesis that EC may be
able to act as APC is based upon the intimate interactions between
EC in microvessels and T cells during transendothelial migration
to lymph nodes or peripheral tissues. That is, EC may acquire
antigenic proteins and present them on MHC class I and II
molecules at their apical surface. The vascular EC that separate
the blood stream from the brain parenchyma is referred to as the
blood brain barrier (BBB). The BBB provides both anatomical and
physiological protection for the central nervous system, regulating
the entry of many substances and blood borne cells into the
nervous tissue. There is increasing evidence of interactions
between T cells and brain endothelium in diseases such as
multiple sclerosis, cerebral malaria (CM) and viral neuropathol-
ogies. Of particular note, the diameter of microvessels, where the
pathology is seen during CM, is smaller than the size of activated
lymphocytes; therefore the latter physically ‘‘brush’’ the EC
surface and can thus interact very closely. Additionally, during
CM, both T cells and monocytes are arrested in brain microvessels
[2] and we recently demonstrated that brain EC can display
antigens from infected erythrocytes on their surface, thereby
possibly initiating immune responses [3].
MHC expression, which is the primary requirement for APC
activity has been demonstrated on EC with both MHC I and II
upregulated following cytokine treatment [4–6]. Moreover, EC may
also qualify as APCs due to the secretion of cytokines, particularly
GM-CSF [7,8]. Some studies using MHC matched donors supports
the model that cultured human EC are able to present antigen and
thus re-activate primed CD4+ T cells [9–11]. However, EC are
specifically able to re-stimulate T cells, but not to prime naı¨ve T cells,
which is a hallmark of ‘‘professional’’ APCs such as dendritic cells
[12–14]. Additional studies using co-cultures of MHC-mismatched
EC and T cells resulted in the activation of both CD4+ and CD8+ T
cells suggesting that EC are able to present alloantigens [15,16].
The body of evidence supporting the role of EC as APC
(reviewed in [17]) led us to investigate the capacity of brain
microvascular EC to act as APC and modulate T cell activation
and proliferation. Here we confirm and expand on previous data
[18] and show that immortalised human brain microvascular
hCMEC/D3 endothelial cells (HBEC) express MHC II and the
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co-stimulatory molecules CD40 and ICOSL following cytokine
stimulation. We also demonstrate that HBEC were able to take up
fluorescently labeled antigens via macropinocytosis and clathrin
coated pits. Moreover in our peripheral blood mononuclear cell
(PBMC)/HBEC co-cultures, HBEC support and promote the
proliferation of both CD4+ and CD8+ T cells suggesting that the
brain endothelium is able to process and present antigens to
allogeneic T cells. Finally, we were able to demonstrate that the
interaction between T cells and HBEC occurs in a 2-way fashion
as the expression of MHC II on HBEC was significantly increased
following co-culture with PBMC. Combined, our data indicates
that EC can act as semi-professional APC, which has important
implications for the presentation of antigens to T cells, resulting in
the activation of the effector T cell response in neuroinfectious
diseases, particularly CM.
Materials and Methods
Ethics Statement
The blood samples used in this study are from anonymous
donors from the Australian Red Cross Blood Bank. Protocol was
approved by the University of Sydney Human Ethics Committee
(Approval #10218).
Cells and cell culture
Immortalised human brain microvascular hCMEC/D3 endo-
thelial cells (HBEC) [18] were cultured in EBM-2 medium (Lonza
CC-3156). Cells were grown on plates pre-coated with rat tail
collagen type I (BD Biosciences). Cytokine activation of HBEC
was performed by treating the cells with 10 ng/ml TNF or 50 ng/
ml IFNc (Peprotech) for 18 h.
Human PBMC preparation
PBMC were separated either from leukopacks or from
heparinized venous blood by conventional Ficoll gradient and
brought to 26106/ml in complete medium. PBMC were frozen in
10% DMSO in FCS and stored in liquid nitrogen. PBMC were
thawed and washed twice in cold medium before use in assays.
T cell isolation and CFSE staining
CD4+ and CD8+ T cells were isolated from freshly thawed
PBMCs using an EasysepH (Stemcell Technologies) negative
selection kit according to the manufacturer’s instructions. For
labeling both isolated T cells and whole PBMCs with Carboxy-
fluorescein succinimidyl ester (CFSE; Invitrogen), cells (at a density
of 107 cells/ml) were incubated for 10 min at 37uC in 5 mM CFSE
in serum free RPMI. The labelling reaction was stopped by the
addition of serum. Cells were then washed 3 times prior to use. For
the quantification of cell proliferation, cells were analysed by flow
cytometry with a reduction in CFSE MFI indicative of cell division.
Flow cytometry
For multicolor flow cytometric analysis, HBEC were incubated in
the presence of fluorochrome-conjugated mAbs against CD105
(SN6), CD106 (STA), CD80 (2D10.4), CD86 (IT2.2), CD40 (5C3),
HLA-DR/MHC II (LN3) and CD275 (MIH12) (all from
eBioscience), CD54 (5.6E; Beckman Coulter) and b2-microglobu-
lin/MHC I (TU¨99; BD Biosciences) as per manufacturer’s instruc-
tions.
Antigen uptake analysis
The ability of HBEC to take up fluorescently labeled protein
was assessed using flow cytometry after the cells were incubated
with either 1 mg/ml Fluorescein isothiocyanate (FITC)-Ovalbu-
min (OVA) or Lucifer Yellow (Invitrogen) at 37uC for 45 min and
washed three times with PBS. Results are expressed as the
percentage increase in mean fluorescence intensity (MFI), which
subtracts any fluorescence detected by nonspecific surface binding
after incubation on ice. The percentage increase in MFI is
calculated as follows; % increase in MFI = [(uptake at 37uC)/
(uptake at 4uC)6100]. To selectively inhibit macropinocytosis and
other actin-dependent mechanisms, HBEC were pre-incubated for
15 min at 37uC with cytochalasin D (CCD; 10 mM; Sigma).
Conjugation assays
The ability of HBEC to form long-lasting conjugates with T
cells was assessed using an in vitro conjugation assay. Briefly, CD4+
and CD8+ T cells were isolated from PBMC using EasySepH.
Isolated T cells and trypsinated HBEC were then labeled with the
membrane-labeling agents, PKH26 (red) and PKH67 (green)
respectively (Sigma). 16105 T cells and 16105 HBEC were co-
incubated for 30 min at 37uC prior to flow cytometric analysis.
Conjugates were deemed to be positive for both PKH26 and
PKH27.
In vitro T cell proliferation assays
HBEC were cultured to confluence in 24 well tissue culture
plates (Corning). Cells were either left under resting conditions or
stimulated with a combination of 10 ng/ml TNF and 50 ng/ml
IFNc for 18 h. 16105 CFSE-labeled PBMCs were added per well
with the following conditions; PBMC alone, 0.3 mg/ml aCD3
(eBioscience; Clone HIT3a) or 0.3 mg/ml aCD3+1 mg/ml
aCD28 (eBioscience; Clone CD28.2). The co-cultures were
incubated for 6 days at 37uC. After 6 days in culture the non-
adherent cells were then collected for staining and flow cytometric
analysis. Non-adherent cells were stained with PE conjugated anti-
human CD4 (eBioscience; Clone OKT4) and PE-Cy5 anti-human
CD8a (Biolegend; Clone HIT8a) prior to multi-colour flow
cytometric analysis. T cell proliferation was then quantitated with
the parameters set to a log scale. A forward scatter vs FL1 was used
to gate on the PBMC population that was positive for CFSE. This
gated population was then used to differentiate between CD4+ T
cells and CD8+ T cells. CFSE histograms depict the number of
events (y-axis) and the fluorescence intensity (x-axis) with
proliferating cells displaying a progressive 2-fold loss in fluores-
cence intensity following cell division, indicative of proliferating
cells. To determine whether cell contact is necessary for EC to
support T cell proliferation, the use of transwells was employed.
16105 PBMC/well were placed in 0.4 mm transwells (Costar) and
co-culture with HBEC performed as outlined above.
MHC II expression on HBEC following co-culture
To assess the expression of MHC II on HBEC following co-
culture with PBMC, HBEC were removed by trypsinisation
following 6 d of co-culture. HBEC were then stained with anti-
human MHC II (HLA-DR; eBioscience). For flow cytometric
analysis CFSE positive cells (PBMC) were excluded by gating to
ensure MHC II analysis was conducted on HBEC only.
Results
HBEC express key molecules for antigen presentation
and T cell activation
For this study we employed a particular line of immortalized
human microvascular EC (HBEC; hCMEC/D3) that recapitulates
many of the key characteristics of primary brain EC and thus has
Brain Endothelium and T Cell Proliferation
PLOS ONE | www.plosone.org 2 January 2013 | Volume 8 | Issue 1 | e52586
been validated as an excellent model of the BBB for in vitro studies
[18–20].
A number of adhesion molecules known to be expressed by
brain endothelium are involved, under inflammatory conditions,
in the migration of activated leukocytes across the BBB. Flow
cytometric analysis of HBEC cells not only confirmed the strong
basal expression of ICAM-1, but also demonstrated a marked up-
regulation following stimulation with TNF and/or IFNc (Fig. 1).
Endoglin (CD105), an EC marker predominantly expressed by
proliferating EC was expressed at high levels basally, with no
regulation in expression seen following pro-inflammatory cytokine
stimulation (Fig. 1). Similarly, MHC I (b2-microglobulin) was
expressed at high levels basally on HBEC with no increase
observed following cytokine stimulation (Fig. 1). This is in contrast
to previous results whereby MHC I expression has been shown to
be upregulated by stimulation with IFNa, -b or –c [21]. Despite
this, our results provide evidence that HBEC, like most cell types,
possess the minimal requirement for antigen presentation to CD8+
T cells. In contrast to MHC I, despite the low basal expression of
MHC II on HBEC cells, its expression was greatly increased upon
the addition of IFNc or TNF+IFNc (Fig. 1), highlighting a
potential role for these cells in antigen presentation to CD4+ T
cells. Previous analysis of MHC II on EC has proved difficult in
vivo, with constitutive expression only detected in post-capillary
venules [22]. Whilst the expression of the co-stimulatory molecules
CD80/CD86 (B7-1/B7-2) was not detected on resting or cytokine-
stimulated HBEC cells, the co-stimulatory molecule, CD40 was
detected following stimulation with IFNc or TNF+IFNc (Fig. 1),
indicating that like MHC II the expression is regulated by IFNc.
Previously, CD40 has been demonstrated to be constitutively
expressed on primary human brain ECs, with this expression
being upregulated following cytokine stimulation [23]. The
expression of this co-stimulatory molecule on brain EC provides
key evidence for their potential role as APC as the binding of
CD40L on helper T cells to CD40 activates ‘APCs’ to upregulate
the expression of more co-stimulatory molecules, increase cytokine
expression and promote T cell differentiation [24]. Finally,
inducible co-stimulator ligand (ICOSL) expression was detected
on HBEC following TNF stimulation (Fig. 1). ICOS and its ligand,
ICOSL are members of the CD28 family of co-stimulators
mediating effector T cell differentiation [25]. Previously, ICOSL
has been detected not only basally on human umbilical vein ECs
but also upregulated by cytokine stimulation [25,26].
HBEC take up antigens using macropinocytosis and
clathrin-coated pits
A recent study from our laboratory demonstrated that during
malaria, the transfer of parasite antigens to ECs can take place [3],
however, the precise mechanisms behind this remain unclear. The
ability of our HBEC to take up soluble antigens was assessed in vitro
using fluorescently labeled antigens in a classic antigen uptake
experiment. The ability of HBEC to take up antigen via
macropinocytosis and clathrin-coated pits was assessed using
Lucifer yellow and FITC-OVA respectively. The amount of
fluorescence incorporated into the cells at 37uC was measured by
flow cytometry with nonspecific surface binding subtracted
following incubation on ice. Interestingly, HBEC were able to
take up FITC-OVA via clathrin-coated pits and macropinocytose
Lucifer yellow (Fig. 2A, C respectively). To further prove that the
uptake of antigen by HBEC was not an experimental artifact, a
specific inhibitor of macropinocytosis and other actin-dependent
mechanisms, cytochalasin D (CCD; 10 mM) was employed [27].
Indeed, following pre-incubation with CCD, both the uptake of
FITC-OVA and Lucifer yellow was significantly inhibited (Fig. 2
B, D) indicating that HBEC have the capacity to take up soluble
antigen in a similar manner as professional APC.
HBEC support the proliferation of activated T cells
As optimal T-cell activation and differentiation in vivo requires
long-lasting T–APC interaction, a classical in vitro conjugate
forming assay was adapted to assess the ability of HBEC to form
conjugates with T cells [28]. Red fluorescently labeled (PKH26)
CD4+ or CD8+ T cells were incubated in suspension with green
fluorescently labeled (PKH67) HBECs with the adherence
between HBEC and T cells examined using flow cytometry.
Figure 1. Expression of markers relevant to antigen presentation and T cell activation on HBEC. Histograms represent flow cytometry
results from unstimulated and cytokine stimulated HBEC cells 18 h following stimulation. HBEC were stimulated with either 10 ng/ml TNF (blue line),
50 ng/ml IFNg (green line), or 10 ng/ml TNF+50 ng/ml IFNg (orange line) and compared to unstimulated cells (red line). Cells were stained with mAbs
against CD54 (ICAM-1), Endoglin (CD105), MHC II (HLA-DR), ICOSL (CD275), CD40, CD80 and CD86 as per manufacturers instructions. Data are
representative of four independent experiments.
doi:10.1371/journal.pone.0052586.g001
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Conjugates were determined to be cells positive for both PKH26
and PKH67. Interestingly, both CD4+ and CD8+ T cells form
conjugates, i.e. cell doublets in suspension, with control (data not
shown) and cytokine activated HBECs, as shown by flow
cytometry (Fig. 2E, F respectively). There were higher percentages
of T cell/HBEC conjugates seen when the HBEC were cytokine
activated (3.6 vs 1.4% for CD4+ and 6.3 vs 2.1% for CD8+).
After determining that HBEC were capable of binding to both
CD4+ and CD8+ T cells, the ability of HBEC to support T cell
proliferation and present alloantigens was assessed by co-culturing
CFSE-labelled donor PBMCs with a confluent monolayer of either
resting or cytokine stimulated HBECs. In addition, the agonistic
antibodies aCD3/aCD28 were also added to the assay to mimic T
cell receptor (TCR) stimulation and co-stimulation respectively
[29]. Six days following co-culture the percentage of CD4+ and
CD8+ T cells proliferating was determined by measuring the
reduction in CFSE MFI (Fig. 3A). While the presence of soluble
aCD3 and aCD28 resulted in a modest increase in proliferating
CD8+ cells, the only significant increase in proliferation was
observed when the PBMC were co-cultured with TNF+IFNcacti-
vated HBEC and aCD3/aCD28 (Fig. 3B), indicating that HBEC
support the proliferation of CD8+ T cells, however, the CD8+ cells
must also be activated via their TCR. Interestingly, CD4+ T cell
proliferation was significantly increased in the presence of both
resting and cytokine-stimulated HBEC (Fig. 3C), however, the
CD4+ cells also must be stimulated via their TCR with aCD3 or
aCD3/aCD28 to observe the HBEC-mediated support of
proliferation. It is most likely that the modest increase in
proliferation for both CD4+ and CD8+ T cells following aCD3
stimulation is indicating that the cells were not stimulated using a
solid phase activation, i.e. plate bound aCD3.
Experiments using transwells have indicated that when the
PBMC were physically separated from the HBEC monolayer
during co-culture, the increase in proliferation over control
samples were greatly reduced (Fig. S1). This was observed for
both CD4+ and CD8+ T cells suggesting that direct interaction
Figure 2. HBEC take up fluorescently labelled antigen via actin-dependent mechanisms and form conjugates with T cells. Flow
cytometry histograms depicting level of uptake of FITC-OVA (A) and Lucifer yellow (C) by HBEC at 37uC (blue line) vs background uptake at 4uC (red
line). Data are representative of three independent experiments. Inhibition of FITC-OVA (B) and Lucifer yellow (D) uptake by HBEC cells pre-incubated
with 10 mM Cytochalasin D (CCD). C, Flow cytometry histogram depicting level of uptake of Lucifer yellow by HBEC at 37uC (blue line) vs background
uptake at 4uC (red line). Data are representative of three independent experiments Percentage increase in mean fluorescence intensity (MFI) is
calculated as follows: (MFI following uptake at 37uC/MFI following uptake at 4uC)6100. Data are pooled from three independent experiments (n = 3
per experiment) and are expressed as mean +/2 SD. ** and *** indicates statistically significant differences between control and CCD treatment as
assessed by Student t test (p, 0.001, p,0.001 respectively). Representative flow cytometry plots indicating the levels of conjugation between HBEC
and CD4+ (E) and CD8+ (F) cells. HBEC were labeled with PKH67 and isolated T cells labeled with PKH26 and equal numbers of cells were co-cultured
for 30 min prior to flow cytometric analysis.
doi:10.1371/journal.pone.0052586.g002
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between HBEC and T cells is required for HBEC-mediated
support of T cell proliferation.
MHC expression on HBEC is upregulated following co-
culture with allogeneic PBMC
To determine whether the interaction between T cells and
HBEC occurs in a two-way fashion, the expression of MHC II on
the HBEC monolayer was determined following 6 days of co-
culture with PBMCs. A significant increase in MHC II-positive
cells was observed when HBEC were co-cultured with aCD3
oraCD3/aCD28 stimulated PBMCs when compared to HBEC
cells alone (Fig. 4A, B) indicating that the donor PBMC were able
to modulate the MHC II expression on the HBEC themselves.
These conjugates likely involve interactions of ICAM-1/LFA-1
and VCAM-1/VLA-4 on EC/T cells respectively in addition to
interactions required for antigen presentation.
Discussion
In this study, we provide for the evidence that microvascular
brain EC are able to act as APCs. Our analysis of MHC and co-
stimulatory molecule expression on HBEC show for the first time
that brain EC are endowed a ‘‘professional’’ costimulatory ligand
of the B7 family, ICOSL. This in conjugation with the expression
of MHC II and CD40 following IFNc stimulation supports the
notion of the brain endothelium being able to present antigens to
and co-stimulate T cells promoting effector CD4+ T cell responses.
Additionally, with constitutively high expression of MHC I,
Figure 3. HBEC support the proliferation of CD4+ and CD8+ T cells. A, CFSE histogram plots of gated CD4+ (left panel) and CD8+ (right panel)
6 days following the start of the co-culture of HBEC and donor PBMC. For co-culture 16105 CFSE-labelled donor PBMC were co-cultured or not with a
confluent monolayer of either resting or 10 ng/ml TNF+50 ng/ml IFNc pre-stimulated HBEC cells. PBMC were either subjected to resting conditions or
stimulation with aCD3 or aCD3/CD28 mAbs. Following 6 days of culture, cells were harvested and stained with CD4 and CD8 mAbs to identify
proliferating cell populations. CFSE histograms depict the number of events (y-axis) and the fluorescence intensity (x-axis) with proliferating cells
displaying a progressive 2-fold loss in fluorescence intensity following cell division, indicative of proliferating cells. Histograms are representative of
four independent experiments with the same donor. Graphical representation of the percentage of CD4+ (B) and CD8+ (C) PBMC proliferating
following 6 days of culture either alone (white bars) or in the presence of resting (grey bars) or cytokine stimulated (black bars) HBEC as outlined
above. Data is pooled from four independent experiments with the same donor. * indicates statistically significant differences between control PBMC
and respective co-culture conditions using a non-parametric Mann-Whitney test (p,0.05).
doi:10.1371/journal.pone.0052586.g003
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HBEC, like most cell types, possess the minimal requirement for
antigen presentation to CD8+ T cells.
Antigen uptake is the first step in antigen-presenting pathways,
and pinocytosis is the major means by which cells sample soluble
protein antigen. Here we show that HBEC are able to take up
soluble antigen using both macropinocytosis and clathrin-coated
pits as pathways for antigen uptake. Whilst liver sinusoidal EC
have been demonstrated to be fully efficient APC in that they
express co-stimulatory molecules [30], take up antigen via the
mannose receptor [31] and are able to cross present exogenous
antigen [32], no previous studies have been conducted on the
ability of HBEC to take up and process antigens. The data
presented here shows for the first time that HBEC are able to take
up soluble antigen using actin-dependent mechanisms, in a
manner similar to ‘professional’ APCs.
In the co-culture assays presented here, HBEC were able to
support and promote the proliferation of TCR-stimulated CD4+
and CD8+ T cells. In these assays, an MLR occurs and the T cells
proliferate due to an MHC mismatch [33]. The demonstration of
antigen-specific activation of human T cells by EC has previously
been hampered by the requirement for MHC-matched EC and T
cells. Some studies using MHC matched donors support the model
that cultured human EC are able to present antigen and activated
CD4+ T cells [9–11]. Moreover, mouse T cell clones or T cells
from TCR-transgenic mice can be stimulated to proliferate in a
peptide-antigen-specific manner by co-culture with MHC-
matched ECs and the relevant protein antigen [14,34]. Addition-
ally, as presented in this study with our HBEC line, co-cultures of
MHC-mismatched EC and T cells result in the activation of CD4+
and CD8+ T cells demonstrating that EC are able to present
alloantigens [15,16]. In this study we have used a widely accepted
assay of allogenic T cell stimulation without well characterised
antigens in order to prepare for future experiments that will
involve defined malarial antigens. In this assay, the separation of
HBEC and T cells resulted in reduced T cell proliferation,
indicating the role of cell-cell contact in this phenomenon. The co-
stimulatory molecules CD40 and ICOSL are likely to be
mediating this effect. ICOSL, a B-7 co-stimulatory family member
was upregulated on HBECs following cytokine stimulation.
Moreover, ICOSL has been shown previously to be a major co-
stimulator in Human umbilical vein EC-mediated T cell
activation, particularly in the re-activation of effector/memory T
cells [12,26]. Another co-stimulatory molecule, CD40, was
constitutively expressed on HBEC and upregulated after IFNc
stimulation (Fig. 1). CD40 regulates the adhesion of CD4+ T cells
to brain endothelium via the interaction with its ligand, CD40L on
T cells, suggesting a potential mechanism by which activated
CD40L expressing T cells could enhance adhesion and migration
of inflammatory cells across the BBB to sites of inflammation in the
human central nervous system [23].
This increase in HBEC MHC II expression has relevance for
CM pathogenesis as MHC II expression on isolated mouse brain
EC has been associated with the genetic susceptibility to CM [35].
Moreover, more recently the HLA ligand, HLA-C1 along with its
cognate natural killer (NK) cell immunoglobulin-like receptor were
shown to be significantly associated with the development of CM
Figure 4. PBMC modulate MHC II expression on HBEC following co-culture. A, Histogram plots of HBEC depicting expression of MHC II
(HLA-DR) 6 days following the start of the co-culture with donor PBMC. 16105 CFSE-labelled donor PBMC were co-cultured with a confluent
monolayer of either resting (left panels) or 10 ng/ml TNF+50 ng/ml IFNc pre-stimulated (right panels) HBEC cells. PBMC were either subjected to
resting conditions or stimulation with aCD3 or aCD3/CD28 mAbs (top, middle lower panels respectively). Histograms are representative of four
independent experiments with the same donor. B, Percentage of MHC II+ HBEC in resting (white bars) vs TNF/IFNc stimulated (black bars) HBEC. Data
is pooled from four independent experiments with the same donor. * indicates statistically significant differences between control HBEC and
respective co-culture conditions using a non-parametric Mann-Whitney test (p,0.05).
doi:10.1371/journal.pone.0052586.g004
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in humans [36]. EC, at least from lymph nodes, can be modulators
of immune responses as they express multiple peripheral tissue
antigens, independent of the autoimmune regulator, AIRE [37],
and can even induce anergy [38]. This, together with our
observation of malarial antigen transfer to brain EC surfaces [3],
opens more possibilities for endothelial-mediated immunopatho-
logical mechanisms in CM. The findings described here are not
only a major interest for understanding CM pathogenesis but also
other neuroinfections involving disruption of endothelial cell
barriers such as neurocysticercosis and toxoplasmosis [39,40].
In summary, we have shown that human brain endothelium
cells express molecules important for T cell stimulation and
activation including CD40, MHC II and ICOSL. They readily
can take up fluorescently labeled antigens via clathrin-coated pits
and macropinocytosis. Moreover, these cells are able to bind to
and promote the proliferation of allogeneic T cells in vitro. Data
presented here supports the hypothesis that HBEC are able to act
as APC. This is particularly pertinent in neuroinfections such as
CM where the diameter of microvessels is smaller than the size of
lymphocytes; the lymphocytes are in constant physical contact
with the EC surface. Additionally, in the brains of both mice and
human with CM, leukocytes (monocytes and T cells) become
arrested in brain microvessels [2] providing further means for
intimate EC/T cell interactions. It has long been established that
CM is a T cell-dependent disease [41,42], with both CD4+ and
CD8+ T cells playing key roles in CM pathogenesis [43,44].
Moreover, this cell-cell contact plays an important role in brain
endothelial activation [45], as assessed notably by a dramatic
increase in plasma levels endothelial microparticles at the time of
CM [46]. The data presented here, in combination with our
recent demonstration that HBEC can transfer antigens from
malarial-infected red blood cells onto their surface, thereby
becoming a target for the immune response, provide key evidence
for HBEC to act as antigen presenting cells with the presentation
of malaria antigens by brain EC to T cells and the potential
activation of cytotoxic mechanisms providing a new explanation
for CM pathogenesis.
Supporting Information
Figure S1 Separation of HBEC and PBMC results in a
reduction in both CD4+ and CD8+ T cell proliferation. Graphical
representation of fold increase in proliferation of aCD3/CD28
stimulated CD4+ and CD8+ T cells co-cultured with TNF/IFNc
stimulated HBEC over unstimulated (control) CD4+ and CD8+ T
cell proliferation. Proliferation assessed by CFSE following 6 days
of co-culture either in 24 well plates (black bars) or in 0.4 mm
transwells (white bars).
(TIF)
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